Chandan Healthcare Reports FY26 Total Income of ₹ 280.67 Cr, EBITDA of ₹ 56.84 Cr, and PAT of ₹ 27.06 Cr

Chandan Healthcare Reports FY26 Total Income of ₹ 280.67 Cr, EBITDA of ₹ 56.84 Cr, and PAT of ₹ 27.06 Cr​

Lucknow, India, May 28, 2026 - Chandan Healthcare Limited, a leading diagnostics provider with a Pan India presence, today announced its audited financial results for the fourth quarter (Q4) and the full fiscal year (FY26) ended March 31, 2026.

The financial results indicate significant growth across key operational metrics. The company reported a Total Income of ₹ 280.67 Cr for FY26, alongside an EBITDA of ₹ 56.84 Cr and a Profit After Tax (PAT) of ₹ 27.06 Cr.

Consolidated Financial Performance​

The company's performance highlights demonstrate robust year-on-year growth. The key financial figures for FY26 versus FY25 are detailed below:


For the fourth quarter alone, the company recorded a Total Income of ₹ 77.41 Cr, up from ₹ 65.07 Cr in Q4 FY25, representing a year-over-year increase of 18.96%. Similarly, EBITDA stood at ₹ 14.25 Cr (up 12.65%) and PAT at ₹ 6.92 Cr (up 14.88%) for Q4 FY26 compared to the previous year.

Strategic Expansion and Growth Momentum​

Commenting on the financial performance, Mr. Amar Singh, Promoter and Chairman & Managing Director of Chandan Healthcare Limited, noted, "We are pleased to conclude FY26 on a strong note with Total Income of ₹ 280.67 Cr, EBITDA of ₹ 56.84 Cr, and PAT of ₹ 27.06 Cr. FY26 has been a year of aggressive expansion, strategic investments, and network scale-up for Chandan Healthcare."

Mr. Singh elaborated that the company continued to strengthen its operational presence across multiple regions. Key initiatives included the expansion of the network through new diagnostic centre launches in Mumbai, Kolkata, and Raipur. The company also accelerated its exclusive partnership rollout with Jeena Sikho across 13 states, including Chandigarh, Bihar, West Bengal, and Maharashtra. Furthermore, Chandan Healthcare strengthened its institutional healthcare presence by securing multiple long-term government healthcare projects in Punjab, Haryana, and Assam.

During the year, the firm also acquired a comprehensive diagnostic centre in Patna, Bihar, offering both pathology and radiology services, and expanded into the franchisee business model by launching over 130 franchise centres during FY26. Building on this momentum, Chandan Healthcare plans to add over 1,000 franchise centres over the next two years.

Key Operational Highlights​

The company reported substantial operational growth across multiple geographies and service lines:

Institutional Growth Through Government Projects
The company secured multiple PPP projects under the Punjab government in areas such as Pathankot, Gurdaspur, and Kapurthala, involving the installation of 1.5 Tesla MRI and 32-slice CT scan systems, with an estimated project value of ₹ 800 Cr over 10 years. Additionally, it was awarded a 10-year MRI project at the 200-bedded Civil Hospital in Rohtak (Haryana) and secured a 10-year PPP project at the Northeast Frontier Railway Central Hospital in Assam for an advanced radiology center.

Scaling Jeena Sikho Partnership
Operational expansion was marked by commencing diagnostic services at a 100+ bed HIIMS partner hospital facility in Dera Bassi, marking the entry into Punjab. The network also expanded through a 600+ bed partner hospital facility in Muradnagar, Meerut, and through new operations in Lucknow and Kota, Rajasthan.

New Market Penetration
Chandan Healthcare strengthened its network reach by launching diagnostic centres in multiple metros and emerging cities. These launches included a diagnostic centre in Mumbai, offering pathology and advanced diagnostic services; launching services in Kolkata; establishing a centre in Chandigarh; and opening a centre in Raipur, Chhattisgarh, which provides pathology and advanced diagnostic services.

Company Overview and Strengths​

Chandan Healthcare Limited, established in 2003, operates as a leading Pan India diagnostics company within the Chandan Group. It currently has a strong presence across 13 states, including Chandigarh, Bihar, West Bengal, Maharashtra, Gujarat, and Delhi. The company operates over 65 diagnostic centers and more than 400 collection centers, offering comprehensive pathology and radiology services.

Key strengths noted by the company include:

• One-Stop Diagnostics: Delivering over 3,500 pathology and radiology tests through 12 NABL accredited labs and 5 NABH MIS-accredited centers, supported by 1,600 skilled professionals.
• Revenue Diversification: Servicing B2C, B2B, and B2G markets through individual diagnostics, hospital partnerships, and government contracts.
• Cost Efficiency: Utilizing refurbished and new high-end machines to optimize costs while maintaining test accuracy.
• Robust Financials: Achieved a Total Income of ₹ 280.67 Cr, EBITDA of ₹ 56.84 Cr, and PAT of ₹ 27.06 Cr in FY26, reflecting strong growth and operational efficiency.

CHANDAN Stock Price Movement​

Shares of Chandan Healthcare Limited today slipped by 4.66% to settle at ₹228.7. The equity saw significant activity in the session, with 100,000 shares traded.